Articles

Medicines Safety Update article

Considering cosmetic injections? Complete this checklist first

Are you aware of the risks associated with cosmetic injections?

Recommended paracetamol doses and labelling rquirements

The TGA will not pursue the development of an alternative quality standard for sunscreen excipient ingredients at this time in 2019.

Safety information: regulators review balloon and stent devices used to unblock blood vessels in the legs

Information for consumers on the use of performance and image enhancing drugs

Changes will be made to the regulation of nappy rash products on 1 January 2020

Medicines Safety Update article

New regulations for stem cell treatments in Australia came into force on 1 July 2019

The transition period for updating medicine ingredient names ends on 30 April 2020.

Medicines Safety Update article

Do your research before consenting to live blood analysis, electrodermal testing and other related tests

Indications proposed by industry during the 2017 public comment period have been published

Australian launch of a new product called Nyxoid nasal spray for opioid overdoses

On 14 December 2018, the TGA issued an infringement notice for export of unlawful medicines from Australia

Infliximab and mycosis fungoides, infliximab and lupus-like syndrome, and medicine shortages mandatory reporting

Reforms relating to accessing unapproved products include modifications to the Special Access Scheme and Authorised Prescriber scheme to allow streamlined access to certain unapproved therapeutic products.

The complementary medicine regulatory reforms include changes that will create a new approval pathway for listed complementary medicines and increase availability of information to support consumer decisions.

The prescription medicines regulatory reforms include changes that will bring medicines to market sooner in Australia, while maintaining a robust framework for safety, quality and efficacy.

Reforms to TGA advisory committees include changes that provide greater efficiencies and a reduction in the number of statutory advisory committees that provide independent advice to the TGA.

Standards minimise risk of misconnections; eltrombopag interference with test results; amniotic fluid tests

Cabozantinib (CABOMETYX) is the first medicine to be registered via the new COR-A pathway

Case studies in Incident Report Investigations; review of reusable biopsy forceps devices; care required with patient lifters